Overview
- Authors:
-
-
Jens Møller
-
European Organization for the Control of Circulatory Diseases (EOCCD), Store Kongensgade 36, Copenhagen K, Denmark
-
H. Einfeldt
-
Krankenhaus St. Georg, Hamburg 1, Germany
Access this book
Other ways to access
Table of contents (14 chapters)
-
-
- Jens Møller, H. Einfeldt
Pages 1-3
-
- Jens Møller, H. Einfeldt
Pages 4-5
-
- Jens Møller, H. Einfeldt
Pages 6-6
-
- Jens Møller, H. Einfeldt
Pages 7-9
-
- Jens Møller, H. Einfeldt
Pages 10-13
-
- Jens Møller, H. Einfeldt
Pages 14-27
-
- Jens Møller, H. Einfeldt
Pages 28-32
-
- Jens Møller, H. Einfeldt
Pages 33-41
-
- Jens Møller, H. Einfeldt
Pages 42-46
-
- Jens Møller, H. Einfeldt
Pages 47-48
-
- Jens Møller, H. Einfeldt
Pages 49-50
-
- Jens Møller, H. Einfeldt
Pages 51-52
-
- Jens Møller, H. Einfeldt
Pages 53-53
-
- Jens Møller, H. Einfeldt
Pages 54-55
-
About this book
For many years now I have devoted much of my time to lecturing and writing on the subject of cardiovascular disease (CVD). In this book I have outlined the development of my approach to this problem. I must admit that the details of my theories have undergone continuous modification as a result of the lessons learned in treating a large number of patients, but the basic message has remained the same. I believe that the delay in the utilization oftestosterone treatment for CVD has arisen from a failure by specialists in endocrinology, biochemistry, physi ology, and cardiology to understand each other's point of view and therefore to effectively coordinate their clinical efforts. This is like four people starting to climb the various faces of a pyramid, unaware of each other's presence until they reach the apex. It is hoped that bringing specialists in these different disciplines together at "summit meetings" will help them discover the true nature of this disease, the cardiovascular specialist understanding the underlying lack of anabolic steroids, and the other three grasping the way in which treatment with these compounds can effectively counteract the metabolic disturbance which is the cause of CVD. Even apart of the language barrier, writing this book has by no means been an easy task. Please consider my situation; one cannot be a cardiologist, endocrinologist, biologist, biochemist, and physiologist all in one person. This fact may open me to criticism.
Authors and Affiliations
-
European Organization for the Control of Circulatory Diseases (EOCCD), Store Kongensgade 36, Copenhagen K, Denmark
Jens Møller
-
Krankenhaus St. Georg, Hamburg 1, Germany
H. Einfeldt